90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.

Author(s): Grillo-Lopez AJ

Affiliation(s): Neoplastic and Autoimmune Diseases Research Institute, Rancho Santa Fe, CA 92067-3797, USA. agrillo1@aol.com

Publication date & source: 2005-02, Semin Oncol., 32(1 Suppl 1):S44-9.

Publication type:

Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, San Diego, CA, and Schering AG, Berlin, Germany) was approved in the United States in 2002 for patients with relapsed or refractory, low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory disease, and in Europe in 2003. This agent has yielded good results in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, for whom limited treatment options are available. Radioimmunotherapy with 90Y-ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher overall and complete response rates than rituximab alone. Furthermore, treatment can be safely administered on an outpatient basis, with minimal disruption to patients' daily routines. The 90Y-ibritumomab tiuxetan treatment regimen, appropriate patient selection, and risk assessment are discussed in this article.